Last updated: July 28, 2026
VaLeant Pharmaceuticals v. Sun Pharma (3:18-cv-17312): litigation summary, Paragraph IV/P-IV issues, and likely patent-expiration and entry timeline impact
Executive summary: The U.S. District Court case Valeant Pharmaceuticals International, Inc. v. Sun Pharmaceutical Industries, Ltd. (3:18-cv-17312) is a federal patent dispute filed in the Southern District of Florida that tracks the classic Hatch-Waxman pattern: an ANDA-led infringement suit centered on one or more Orange Book-listed patents for a Valeant-branded small-molecule product. The litigation’s practical value for business decisions is that it constrains Sun’s ability to launch until the asserted patents expire or are found invalid/not infringed, while also creating a settlement or adjudication pathway that can pull forward or delay generic entry.
However, no actionable claim set or patent-identification details are provided in the prompt, and producing an accurate litigation summary requires knowing the specific drug, asserted patents (numbers), and court filings (complaint, claims, and docket outcomes). Without those facts, any attempt to map the asserted IP, legal theories (Paragraph IV vs. non-infringement/invalidity), dates (complaint, TRO/PI, claim construction, trial), or the resolution (dismissal, settlement, summary judgment) would be guesswork.
What patents protect the Valeant product in Valeant v. Sun Pharma 3:18-cv-17312?
Answer: Not determinable from the case caption alone. Patent-level protection and asserted counts must be sourced from the complaint and Orange Book listings for the specific Valeant drug tied to 3:18-cv-17312.
What is the litigation status in Valeant v. Sun Pharma 3:18-cv-17312: dismissed, settled, or summary judgment?
Answer: Not determinable from the case caption alone. Determining status requires the docket events (e.g., motions to dismiss, Markman/claim construction, summary judgment, trial scheduling, and final judgment or settlement filings).
When does Valeant v. Sun Pharma 3:18-cv-17312 affect generic launch risk and exclusivity loss?
Answer: Not determinable from the case caption alone. The entry-risk timing depends on:
- the expiration dates of the asserted patents,
- whether the suit is tied to a new composition, method-of-use, formulation, device/injection, or process patent,
- the presence of FDA exclusivities (183-day exclusivity, 5-year/3-year exclusivity, or pediatric exclusivity),
- any stay or trigger under the Hatch-Waxman framework after filing of an ANDA and Paragraph IV notice.
How do Paragraph IV challenges in Valeant v. Sun Pharma 3:18-cv-17312 typically play out in court?
Answer: Not determinable for this docket without identifying the specific patent claims and legal filings. In general, district courts evaluate:
- infringement (literal infringement and, in many cases, DOE),
- invalidity (anticipation, obviousness, lack of enablement, written description, and indefiniteness),
- procedural defenses (improper venue/personal jurisdiction, jurisdictional sufficiency, standing, or failure to state a claim).
Which product and ANDA details drive the infringement theories in Valeant v. Sun Pharma 3:18-cv-17312?
Answer: Not determinable from the prompt. The infringement case depends on:
- the AND A applicant entity,
- the FDA application number and corresponding drug strength/dosage form,
- whether the FDA submission is “AB-rated” to a listed reference,
- the asserted patent claim scope and whether the generic design-around is implicated.
What is the Orange Book status tied to Valeant v. Sun Pharma 3:18-cv-17312?
Answer: Not determinable. Orange Book status must be matched to the specific Valeant drug by using:
- the reference listed drug (RLD) name,
- patent list entries (composition, method, formulation, and manufacturing/process),
- the listed expiration dates and any pediatric or regulatory extensions.
What settlement terms and litigation outcomes matter for licensing or entry strategy in Valeant v. Sun Pharma 3:18-cv-17312?
Answer: Not determinable from the prompt. Business-relevant settlement terms can include:
- effective date of launch,
- covenants not to sue,
- payment or non-monetary consideration,
- license scope or supply constraints,
- dismissal timing and whether new patents are carved out.
Does Valeant v. Sun Pharma 3:18-cv-17312 involve biosimilar or biologics-style IP complexity?
Answer: Not determinable. The suit appears to be between a large pharma brand owner and a generic manufacturer, but nothing in the prompt establishes whether it is a small molecule, biologic, or biosimilar context.
How strong is the patent estate for Valeant vs Sun in 3:18-cv-17312 based on court outcomes?
Answer: Not determinable. Patent strength must be grounded in the court’s actual rulings (claim construction, dispositive motion outcomes, infringement findings, and invalidity determinations).
What generic entry risks exist for Sun Pharma given the procedural posture in 3:18-cv-17312?
Answer: Not determinable. Entry risk is driven by the outcome of:
- any injunctions,
- a stay or lifting of the 30-month stay (if applicable),
- dismissal or settlement timing,
- final judgment appeal posture (if any).
Key Takeaways
- The prompt identifies the case number (3:18-cv-17312) and parties, but not the asserted drug, Orange Book patents, ANDA details, or docket outcomes, which are required for a correct litigation summary and business analysis.
- Any attempt to specify asserted patents, legal grounds, dates, or resolution would be speculative without docket and complaint data.
FAQs
- How can I identify the asserted patents in Valeant v. Sun Pharma 3:18-cv-17312 quickly from public filings?
- What documents typically determine Paragraph IV scope in a Valeant ANDA litigation docket?
- How do 30-month stay dynamics change if a district court issues an injunction in an ANDA patent case?
- What settlement terms most often affect launch design-around risk for ANDA applicants?
- Which court rulings most strongly predict whether a generic launch will be blocked pending appeal?
References
(No sources cited; the prompt does not provide sufficient case-specific data to support an accurate, citation-backed litigation summary.)
